Want to see JP:4564 full AI Analyst Report?
OncoTherapy Science (4564) AI Stock Analysis
OncoTherapy Science
(TSE/TYO:4564)
The overall stock score of 42 reflects significant challenges. The company's financials show ongoing losses and cash burn, though a strong balance sheet provides some cushion. Technical indicators are bearish with price below all moving averages, and valuation is unfavorable due to negative earnings. The absence of earnings call or corporate events does not alter the assessment. OncoTherapy Science remains a high-risk biotech investment.
OncoTherapy Science (4564) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 7.35B
- Dividend Yield
- ―
- Average Volume (3M)
- 183.43M
- Price to Earnings (P/E)
- -7.6
- Beta (1Y)
- 1.04
- Revenue Growth
- -8.58%
- EPS Growth
- 19.03%
- Country
- Japan
- Employees
- 46
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
OncoTherapy Science Business Overview & Revenue Model
Company Description
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound th...
How the Company Makes Money
The company’s monetization is generally tied to commercializing oncology drug candidates and related technologies through development and partnering, including potential revenue from licensing/out-licensing, collaborative research arrangements, and m...
OncoTherapy Science Financial Statement Overview
Summary
The company's financial performance is mixed: revenue declined 5% and net losses persist, but a strong debt-free balance sheet with substantial equity provides a runway for R&D. The combination of weak income and cash flow, offset by solid equity, results in a below-average score.
Income Statement
22NegativeBalance Sheet
85Very PositiveCash Flow
25Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 749.75M | 808.53M | 750.05M | 610.12M | 1.13B | 332.48M |
| Gross Profit | -12.76M | 13.96M | -12.76M | -177.72M | 41.69M | 19.54M |
| EBITDA | -126.67M | -810.38M | -14.92M | -165.50M | -1.10B | -1.59B |
| Net Income | -815.05M | -910.64M | -815.28M | -1.29B | -1.12B | -1.56B |
Balance Sheet | ||||||
| Total Assets | 1.16B | 2.36B | 1.16B | 867.27M | 1.51B | 3.37B |
| Cash, Cash Equivalents and Short-Term Investments | 833.88M | 2.09B | 833.88M | 527.66M | 1.12B | 2.90B |
| Total Debt | 51.07M | 0 | 51.07M | 106.85M | 0 | 0 |
| Total Liabilities | 426.09M | 217.37M | 426.09M | 513.61M | 656.27M | 291.28M |
| Stockholders Equity | 729.11M | 2.14B | 729.11M | 353.67M | 855.17M | 3.08B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -984.97M | -815.30M | -1.23B | -800.29M | -1.81B |
| Operating Cash Flow | 0 | -922.75M | -815.02M | -1.23B | -794.90M | -1.76B |
| Investing Cash Flow | 0 | -63.22M | -279.00K | -33.35M | -20.32M | -52.23M |
| Financing Cash Flow | 0 | 2.24B | 1.12B | 671.37M | 95.95M | 0 |
OncoTherapy Science Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4564, the sentiment is Negative. The current price of 17.00 is below the 20-day moving average (MA) of 18.60, below the 50-day MA of 20.34, and below the 200-day MA of 21.04, indicating a bearish trend. The MACD of -0.87 indicates Positive momentum. The RSI at 43.46 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4564.
OncoTherapy Science Peers Comparison
Overall Rating
JP:456561Neutral
JP:457960Neutral
JP:458855Neutral- JP:456442Neutral
JP:457142Neutral
JP:458741.5Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4565 | 61Neutral | JPY 133.37B | -16.67 | -8.51% | ― | 23.72% | 12.48% |
| JP:4579 | 60Neutral | JPY 16.61B | 71.28 | ― | ― | 20.64% | ― |
| JP:4588 | 55Neutral | JPY 223.32B | -137.55 | ― | ― | 1662.38% | 42.86% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4564 | 42Neutral | JPY 7.35B | -7.63 | -42.79% | ― | -8.58% | 19.03% |
| JP:4571 | 42Neutral | JPY 7.18B | -5.87 | -33.61% | ― | 74.24% | -7.78% |
| JP:4587 | 42Neutral | JPY 145.02B | -39.74 | -7.17% | ― | 0.62% | 27.66% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4564 | OncoTherapy Science, Inc. | 18.00 | -6.00 | -25.00% | |
| JP:4587 | Peptidream | 1117.00 | -414.00 | -27.04% | |
| JP:4565 | Sosei Group Corporation | 1440.00 | 637.00 | 79.33% | |
| JP:4571 | NanoCarrier Co., Ltd. | 79.00 | -79.00 | -50.00% | |
| JP:4579 | RaQualia Pharma Inc. | 638.00 | 110.00 | 20.83% | |
| JP:4588 | Oncolys BioPharma, Inc. | 7560.00 | 6795.00 | 888.24% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 11, 2026